These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 32178286)

  • 1. Serum Has Higher Proportion of Janus Kinase 2 V617F Mutation Compared to Paired EDTA-Whole Blood Sample: A Model for Somatic Mutation Quantification Using qPCR and the 2
    Barra GB; Santa Rita TH; Almeida ALSC; Jácomo RH; Nery LFA
    Diagnostics (Basel); 2020 Mar; 10(3):. PubMed ID: 32178286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR.
    Waterhouse M; Follo M; Pfeifer D; von Bubnoff N; Duyster J; Bertz H; Finke J
    Ann Hematol; 2016 Apr; 95(5):739-44. PubMed ID: 26931113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. JAK2 V617F mutation can be reliably detected in serum using droplet digital PCR.
    Nystrand CF; Ghanima W; Waage A; Jonassen CM
    Int J Lab Hematol; 2018 Apr; 40(2):181-186. PubMed ID: 29150911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superiority of Droplet Digital PCR Over Real-Time Quantitative PCR for
    La Rocca F; Grieco V; Ruggieri V; Zifarone E; Villani O; Zoppoli P; Russi S; Laurino S; Falco G; Calice G; Marinaccio A; Natalicchio MI; Albano F; Musto P
    Diagnostics (Basel); 2020 Mar; 10(3):. PubMed ID: 32150880
    [No Abstract]   [Full Text] [Related]  

  • 5. [A novel modi cation of real-time AS-qPCR by using locked nucleic acid-modified oligonucleotide probe as wild type allele amplification blockers for quantitative detection of the JAK2 V617F mutation].
    Shao DH; Liang GW; He ML; Cao QY
    Zhonghua Xue Ye Xue Za Zhi; 2013 May; 34(5):421-5. PubMed ID: 23688754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Implications of Quantitative JAK2 V617F Analysis using Droplet Digital PCR in Myeloproliferative Neoplasms.
    Lee E; Lee KJ; Park H; Chung JY; Lee MN; Chang MH; Yoo J; Lee H; Kong SY; Eom HS
    Ann Lab Med; 2018 Mar; 38(2):147-154. PubMed ID: 29214759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs.
    Link-Lenczowska D; Pallisgaard N; Cordua S; Zawada M; Czekalska S; Krochmalczyk D; Kanduła Z; Sacha T
    Ann Hematol; 2018 Dec; 97(12):2299-2308. PubMed ID: 30056580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory.
    Merker JD; Jones CD; Oh ST; Schrijver I; Gotlib J; Zehnder JL
    J Mol Diagn; 2010 Jan; 12(1):58-64. PubMed ID: 19959796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accurate quantitation of JAK2 V617F allele burden by array-based digital PCR.
    Kinz E; Leiherer A; Lang AH; Drexel H; Muendlein A
    Int J Lab Hematol; 2015 Apr; 37(2):217-24. PubMed ID: 24963593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2 V617F mutant allele detection.
    Zapparoli GV; Jorissen RN; Hewitt CA; McBean M; Westerman DA; Dobrovic A
    BMC Cancer; 2013 Apr; 13():206. PubMed ID: 23617802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Usefulness of real-time semi-quantitative PCR, JAK2 MutaScreen kit for JAK2 V617F screening].
    Chae H; Lee JH; Lim J; Jung SW; Kim M; Kim Y; Han K; Cho BS; Cho SG; Lee JW; Min WS
    Korean J Lab Med; 2009 Jun; 29(3):243-8. PubMed ID: 19571623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laboratory-developed Droplet Digital PCR Assay for Quantification of the JAK2
    Liu Y; Han C; Li J; Xu S; Xiao Z; Guo Z; Rao S; Yao Y
    Glob Med Genet; 2024 Jun; 11(2):132-141. PubMed ID: 38585044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases.
    Rapado I; Albizua E; Ayala R; Hernández JA; Garcia-Alonso L; Grande S; Gallardo M; Gilsanz F; Martinez-Lopez J
    Ann Hematol; 2008 Sep; 87(9):741-9. PubMed ID: 18575865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved diagnosis of the transition to JAK2 (V⁶¹⁷F) homozygosity: the key feature for predicting the evolution of myeloproliferative neoplasms.
    Gonzalez MS; De Brasi CD; Bianchini M; Gargallo P; Stanganelli C; Zalcberg I; Larripa IB
    PLoS One; 2014; 9(1):e86401. PubMed ID: 24475114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of JAK2V617F mutation assessment employing different molecular diagnostic techniques.
    Veneri D; Capuzzo E; de Matteis G; Franchini M; Baritono E; Benati M; Solero GP; Ambrosetti A; Quaresmini G; Pizzolo G
    Blood Transfus; 2009 Jul; 7(3):204-9. PubMed ID: 19657484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Risk Janus Kinase 2 V617F Allele Burden in a Seven-Year Cohort of Patients with Myeloproliferative Neoplasms.
    Chatambudza M; Skhosana L; Ketseoglou I; Wiggill T
    Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas12a-Based Ultrasensitive and Rapid Detection of
    Chen M; Zhang C; Hu Z; Li Z; Li M; Wu L; Zhou M; Liang D
    Biosensors (Basel); 2021 Jul; 11(8):. PubMed ID: 34436049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms.
    Fontanelli G; Baratè C; Ciabatti E; Guerrini F; Grassi S; Del Re M; Morganti R; Petrini I; Arici R; Barsotti S; Metelli MR; Danesi R; Galimberti S
    Int J Lab Hematol; 2015 Dec; 37(6):766-73. PubMed ID: 26189968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The G allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly associated with JAK2 V617F-positive myeloproliferative neoplasms.
    Trifa AP; Cucuianu A; Petrov L; Urian L; Militaru MS; Dima D; Pop IV; Popp RA
    Ann Hematol; 2010 Oct; 89(10):979-83. PubMed ID: 20422415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms.
    Takahashi K; Patel KP; Kantarjian H; Luthra R; Pierce S; Cortes J; Verstovsek S
    Blood; 2013 Nov; 122(23):3784-6. PubMed ID: 24068492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.